| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.3238/ARZTEBL.2016.0470 |
| P8608 | Fatcat ID | release_kb5ijjmfynfxrmlaloge7awgwu |
| P932 | PMC publication ID | 4973001 |
| P698 | PubMed publication ID | 27476706 |
| P50 | author | Hermann Einsele | Q1610986 |
| P2093 | author name string | Martin Schmidt-Hieber | |
| Stefan Knop | |||
| Stephan Fuhrmann | |||
| Susanne Strifler | |||
| Christian Gerecke | |||
| P2860 | cites work | Bisphosphonates in multiple myeloma: a network meta-analysis | Q24197839 |
| Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study | Q24653006 | ||
| Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group | Q28207984 | ||
| Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial | Q28252396 | ||
| Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial | Q33410172 | ||
| Venous thromboembolism in multiple myeloma | Q33413686 | ||
| Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma | Q33415759 | ||
| High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-l | Q33416028 | ||
| Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma | Q33416418 | ||
| Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial | Q33417762 | ||
| A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival | Q33957196 | ||
| Lenalidomide after stem-cell transplantation for multiple myeloma | Q34273726 | ||
| International staging system for multiple myeloma | Q34408882 | ||
| International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma | Q34450381 | ||
| Prevalence of monoclonal gammopathy of undetermined significance | Q34506801 | ||
| Curing myeloma at last: defining criteria and providing the evidence | Q34508313 | ||
| Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma | Q34815786 | ||
| Review of 1027 patients with newly diagnosed multiple myeloma | Q35045634 | ||
| Guidelines for treatment and prevention of venous thromboembolism among patients with cancer | Q35174604 | ||
| Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report | Q35220639 | ||
| European Myeloma Network guidelines for the management of multiple myeloma-related complications | Q36115636 | ||
| ??? | Q28082855 | ||
| Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders | Q36508844 | ||
| Multiple myeloma: causes and consequences of delay in diagnosis | Q36936572 | ||
| Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma | Q37038414 | ||
| DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma | Q37350545 | ||
| Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy | Q37353007 | ||
| Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. | Q37835574 | ||
| Body mass index and risk of multiple myeloma: a meta-analysis of prospective studies | Q37847524 | ||
| The prognostic significance of cytogenetics and molecular profiling in multiple myeloma | Q37847667 | ||
| International Myeloma Working Group recommendations for global myeloma care | Q38157532 | ||
| Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma. | Q38554884 | ||
| Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century | Q40784538 | ||
| Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma | Q41700620 | ||
| Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma | Q41756273 | ||
| Autologous transplantation and maintenance therapy in multiple myeloma | Q41756278 | ||
| Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. | Q42914716 | ||
| Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial | Q42940540 | ||
| Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents | Q43410456 | ||
| Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma | Q43662977 | ||
| Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial | Q43700291 | ||
| Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma | Q43726973 | ||
| The role of second autografts in the management of myeloma at first relapse. | Q44204181 | ||
| Transplantation as salvage therapy for high-risk patients with myeloma in relapse | Q44245114 | ||
| Can multiple myeloma become a curable disease? | Q45323952 | ||
| Bortezomib or high-dose dexamethasone for relapsed multiple myeloma | Q46549268 | ||
| Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. | Q47826998 | ||
| Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | Q57904272 | ||
| Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma | Q58415969 | ||
| Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study | Q60203571 | ||
| A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome | Q71123629 | ||
| Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization | Q71974115 | ||
| Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years | Q74502702 | ||
| How I treat relapsed myeloma | Q86526740 | ||
| P433 | issue | 27-28 | |
| P921 | main subject | multiple myeloma | Q467635 |
| P1104 | number of pages | 7 | |
| P304 | page(s) | 470-476 | |
| P577 | publication date | 2016-07-01 | |
| P1433 | published in | Deutsches Ärzteblatt international | Q27722165 |
| P1476 | title | The Diagnosis and Treatment of Multiple Myeloma | |
| P478 | volume | 113 |
| Q47161145 | Anaesthesia for fixation of repeated pathological fractures in a patient with multiple myeloma |
| Q92311037 | Case of Stroke from Cerebral Vasculitis following Carfilzomib, Lenalidomide, and Dexamethasone Therapy in a Patient with Relapsing Multiple Myeloma |
| Q92533652 | Evodiamine Selectively Inhibits Multiple Myeloma Cell Growth by Triggering Activation of Intrinsic Apoptosis Pathway |
| Q97073531 | Glycolysis is suppressed by DCZ0801-induced inactivation of the Akt/mTOR pathway in Multiple Myeloma |
| Q47134329 | Monoclonal IgM Gammopathy and Waldenström's Macroglobulinemia |
| Q92356622 | Multiple myeloma with testicular involvement: A case report |
| Q99711905 | Patient-Reported Outcomes and Assessment of Quality of Life: A Focus on Multiple Myeloma |
| Q49649026 | Prognostic Value of IL-10 and Its Relationship with Disease Stage in Iranian Patients with Multiple Myeloma |
| Q90086600 | The World Health Organization classification of odontogenic and maxillofacial bone tumors: An appraisal |
| Q97423139 | Uncommon Presentations of Multiple Myeloma |
| Q64096591 | Variability of serum novel serum peptide biomarkers correlates with the disease states of multiple myeloma |
| Q90601781 | [Management of osseous complications in multiple myeloma] |
Search more.